RespireRx Pharmaceuticals — Investor Presentation (October 2016)
41 slides from RespireRx Pharmaceuticals's investor presentation, Oct 17, 2016
Slide 1: Medicines for Respiratory Diseases
Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases
Slide 2: Forward Looking Statements
Forward Looking Statements A) The matters discussed in this presentation that are not historical facts are "forward- looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and we intend that such forward-looking stat
Slide 3: Breath quote
Breath GQ RespireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." — Abbot George Burke
Slide 4: Company Focus
Company Focus Gd RespireRx o Sleep Apneas = Dronabinol for Obstructive Sleep Apnea (OSA) = Ampakines for Central Sleep Apnea (CSA) o Drug-induced Respiratory Depression (RD) - Ampakines = Acute use — surgical anesthesia/sedation = Semi-acute use — post-surgical pain management with opioids = Chronic
Slide 5: Innovative Medicines for Respiratory Diseases
Innovative Medicines for Respiratory Diseases Gd Resp pireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 development programs o Additional pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent applicati
Slide 6: Respiratory Diseases Product Pipeline
RespireRx Pharmaceuticals Inc Respiratory Diseases Product Pipeline Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea T_—_————<<<, Cental Soep Apnea — a? CX1739 Opioit.nduced RO _——p Spinal Cord Injury —7 CX717 Opioid-induced RD —————, Cx1942 Drug-induced RD. rae =)
Slide 7: Dronabinol for Obstructive Sleep Apnea
Dronabinol for Obstructive Sleep Apnea Pharmaceuticals Inc
Slide 8: Obstructive Sleep Apnea
Obstructive Sleep Apnea Ad RespireRx o Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed o The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sl
Slide 9: Completed Phase 2A Trial of Dronabinol in OSA
Completed Phase 2A Trial of Dronabinol in OSA Gd RespireRx o Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA o Placebo (N=5) or dronabinol (N=17) for 21 days = 2.5, 5 and 10 mg/night studied with weekly dose escalation o Overnight polysomnogram (PSG) at bas
Slide 10: Dronabinol: Breakthrough Treatment for OSA
Dronabinol: Breakthrough Treatment for OSA Gd Resp pireRx Pharmaceuticals Inc o Mechanism of Action = Dronabinol is (delta 9) THC, a cannabinoid agonist o Background = Schedule III drug available by prescription, with a low risk of addiction = Approved for the treatment of anorexia in AIDS patients
Slide 11: Dronabinol Proven to Reduce Apnea in OSA Subjects
Dronabinol Proven to Reduce Apnea in OSA Subjects Apnea/Hypopnia Index (AHI) % change from baseline 40% 30% 20% 10% 0% 10% 20% 30% 40% P=0.17 Placebo Dronabinol RespireRx Pharmaceuticals Inc 11
Slide 12: Apnea Suppression as a Function of Dose and Time
Apnea Suppression as a Function of Dose and Time RN RespireRx nespirek Inc 2 4 4 ; 1st Half a 2nd Half “s n=17 n=13 n=8 ° AAHI versus Baseline 8 5 The plasma half-life of dronabinol is 2 — 4 hours. 12
Slide 13: Completed Dronabinol Phase 2B Clinical Trial in OSA
Completed Dronabinol Phase 2B Clinical Trial in OSA A)Resp ireRx o Sponsored and led by U of Illinois o 4 major centers, fully funded by NIH o Doses: Placebo, 2.5 mg, 10 mg qd o 6 weeks dosing o Trial completed o Data expected Q4/2016 o Meet with FDA after trial completion to determine registration
Slide 14: The Dronabinol Opportunity
The Dronabinol Opportunity Ad RespireRx Pharmaceuticals Inc Impact on Patient Commercial Opportunity First medicine available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly expands pre
Slide 15: Protecting Dronabinol in the Market
Protecting Dronabinol in the Market A) RespireRx Pharmaceuticals Inc o Issued Method-of-Use patent for dronabinol in OSA = Expires in 2025 o Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Off-label use of generics and medical
Slide 16: Ampakines for Opioid-Induced Respiratory Depression
Ampakines for Opioid- Induced Respiratory Depression 16
Slide 17: Translational Approaches to Respiratory Disorders
Translational Approaches to Respiratory Disorders — A Short Course AS) F AMPAKINI Voice «$10 Dose CX1739 (mg/kg) IE 100 pA 50ms 2 RespireRx Pharmaceuticals Inc Brain stem nuclei that regulate breathing contain opioid and AMPA glutamate receptors that inhibit and excite, respectively Ampakines act as
Slide 18: CX717 Prevents Opioid-induced Respiratory Depression in Humans
CX717 Prevents Opioid-induced Respiratory Depression in Humans — Target Engagement RespireRx Pharmaceuticals Inc 16: NS + C— Placebo 5 0X717 12: ™P<0.01 NS - Not Significant Breaths/min o 4 das the basal respiratory rate. N= 15 and 16 per group. CX717 dose is 1500mg. Oertel et al., (2010) Clin Pharm
Slide 19: CX717 Does Not Interfere With the Analgesic Properties of Opioids
CX717 Does Not Interfere With the Analgesic Properties of Opioids AQ RespireRx cated atte Inc Analgesia 2.0: [Placebo > 15: @CX717 & 2 a 5 1.0 NS_ 2) i= S o 0.5: Delivery of a electrical stimulation to finger ’ 0.0: Alfentanil reduced the pain sensitivity Baseline +Alfentanil +Naloxone (produced ana
Slide 20: CX1739: A Third Generation, Oral Ampakine
CX1739: A Third Generation, Oral Ampakine in Phase 2 RespireRx Pharmaceuticals Inc o Targeted Indications = Central Sleep Apnea (CSA) = Reversal and prevention of opioid-induced Respiratory Depression = Combination formulation with an opioid for treatment of chronic pain o Stage of Development = Suc
Slide 21: CX1739: Phase 2A in Opioid-Induced Respiratory Depression
ReSPIren Inc CX1739: Phase 2A in Opioid-Induced Respiratory Depression WR RespireRx Antagonism of Remifentanil-Induced Respiratory Depression by CX1739 in Two Frotocol Clinical Models of Respiratory Depression Design Randomized, Blinded, Placebo-controlled, Cross-Over with Dose Escalation Dosing 17
Slide 22: CX1739: Phase 2A Overall Study Design
CX1739: Phase 2A — Overall Study Design Resp pireRx Pharmaceuticals Inc STAGE 1 STAGE 2 Double-blind, Placebo-Controlled Crossover Open-label, Dose Ascending ox1739 oxt739 300 mg 300 mg Screening _Baseline \ A oxt39 extra0 case marae 600 mg 900 mg Randomize Placebo Placebo Week 1 Week 2 Week 3 Week
Slide 23: CX1739: Phase 2A Daily Protocol
CX1739: Phase 2A — Daily Protocol RespireRx Pharmaceuticals Inc Placebo REMI 1 — bolus injection REMI 2 —continuous infusion X1739 Model of acute overdose Model of chronic oral use i T 1 0 3.0 3.5 4 hours 23
Slide 24: CX1739: Phase 2A Safety
CX1739: Phase 2A — Safety CAS) Resp ireRx eet Inc s SAFETY DATA “ T 2 + CX1739 was safe and well tolerated with no SAEs Most frequent AEs were nausea, vomiting, headache and dizziness, all of which are : common side effects of opioids . 39 of 49 AEs occurred after 2 q remifentanil ° ‘| 05 05-1 1-15
Slide 25: Ampakines for Central Sleep Apnea
Ampakines for Central Sleep Apnea Pharmaceuticals Inc 25
Slide 26: Central Sleep Apnea (CSA)
Central Sleep Apnea (CSA) A)Resp ireRx o Lack of drive from the brain to breathe during sleep o CSA Patients = 70% of chronic narcotic users = Up to 40% of heart failure patients = 5% of sleep apnea patients are idiopathic o No medicine or device is approved for CSA 26
Slide 27: CX1739: Completed Phase 2A in Sleep Apnea Single Dose
CX1739: Completed Phase 2A in Sleep Apnea — Single Dose RespireRx Pharmaceuticals Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a si
Slide 28: Patient Selection: CX1739 More Effective in Mixed and Central Sleep Apneas
Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas RN RespireRx Pharmaceuticals Inc Obstructive Apneas Mixed Apneas Central Apnea BRS & s Apnea Index (Eventsfhr) eansB a Apnea Index (Eventsfhr) cana aaa Apnea Index (Eventsfhr) on & 2 © Ss e e se ¢ e & & %e , “ly
Slide 29: CX1739: Proposed Phase in Sleep Apnea Multiple Dose
CX1739: Proposed Phase 2 in Sleep Apnea — Multiple Dose as RespireRx nespire’ Inc Evaluation of CX1739 for the Treatment of Central Sleep Apnea in Patients on Chronic Protocol eee Opioid Therapy + Randomized, Blinded, Placebo-controlled, Multiple Dose Study at Multiple Sites Design * Subjects with a
Slide 30: Ampakines for Breathing Disorders due to Spinal Cord Injury
Ampakines for Breathing Disorders due To Spinal Cord Injury
Slide 31: CX717: Second Generation Oral Ampakine
CX717: Second Generation Oral Ampakine in Phase 2 RespireRx Pharmaceuticals Inc o Targeted Indications = Spinal Cord Injury = Combination formulation with an opioid for treatment of chronic pain o Stage of Development = Completed 6 Phase 1 and 4 Phase 2 studies = Two positive Phase 2A trials in opio
Slide 32: CX717: Spinal Cord Injury
CX717: Spinal Cord Injury RespireRx Pharmaceuticals Inc Incidence * Estimated 276,000 people with SCI in the US, with 12,000 new cases per year + ~92,000 with respiratory distress * Eligible for Orphan Status Breathing problems are substantial after SCI * Approximately half of all SCls occur in the
Slide 33: CX717 Animal Models of Spinal Cord Injury
CX717 — Animal Models of Spinal Cord Injury RN RespireRx Pharmaceuticals Inc Unilateral hemi-transections at the level of the 2" cervical vertebra are performed on rats and electrical activity is recorded from phrenic nerves, which innervate the diaphragm and contribute to the regulation of breathin
Slide 34: CX717: Proposed Phase in Spinal Injury Multiple Dose
CX717: Proposed Phase 2 in Spinal Injury — Multiple Dose RespireRx Pharmaceuticals Inc Evaluation of CX717 for the Treatment of Breathing Disorder in Patients with Protocol scl Design Ascending Dose Study Dosing BID doses of 250 mg, 500mg and 750 mg CX717 daily for 28 days Primary: Study To evaluate
Slide 35: Summary
Summary a: Pharmaceuticals Inc 35
Slide 36: Respiratory Diseases Product Pipeline
RespireRx Pharmaceuticals Inc Respiratory Diseases Product Pipeline Compound Indication Preclinical Phase 1 Phase 2 Dronabinol Obstructive Sleep Apnea T_—_————<<<, Cental Soep Apnea — a? CX1739 Opioit.nduced RO _——p Spinal Cord Injury —7 CX717 Opioid-induced RD —————, Cx1942 Drug-induced RD. rae =)
Slide 37: Development Milestones
Development Milestones Resp pireRx Pharmaceuticals Inc 4Q2016 | 1Q2017 | 2Q2017 | 3Q2017 | 4Q2017 | 1Q2018 CX1739 RD Clinical Trial at Duke CSA Clinical Trial pending results of RD Trial Formulation, PK and ADME CX717 FDA Regulatory Spinal Cord Injury Clinical Trial Ampakine/Opiate Combination Formu
Slide 38: Capital Structure & Market Metrics
Capital Structure (rounded) & Market Metrics RN RespireRx Total as of October 13, 2016 Common Stock 2,019,000 Common Stock Equivalents of Convertible Notes (estimated) 29,000 Common Stock Equivalents of all Options and Warrants Granted (excludes 371,000 reserved for equity plans) 1,745,000 Total 3,7
Slide 39: Management and Directors
Management and Directors James Manuso Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell Katie MacFarlane James Sapirstein John Greer President, CEO & Vice Chairman CSO & Chairman VP, Secretary/Treasurer, Director CFO, Director Senior VP, R& D Director Senior VP, Napo Pharmaceuticals Direc
Slide 40: Innovative Medicines for Respiratory Diseases
Innovative Medicines for Respiratory Diseases Gd Resp pireRx Pharmaceuticals Inc o Two proprietary, small molecule platforms o Three Phase 2 development programs o Additional pre-clinical programs o Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent applicati
Slide 41: Medicines for Respiratory Diseases
Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO Medicines for Respiratory Diseases
RespireRx Pharmaceuticals — Investor Presentation (October 2016) on 6ix